Understanding Prolactinomas: Diagnosis and Treatment Options

Prolactinomas, benign tumors of the pituitary gland that produce excess prolactin, can lead to significantly elevated serum prolactin levels. A serum concentration above 2000 mU/L (approximately 100 ng/mL) is often indicative of a prolactinoma, with levels in larger tumors potentially exceeding 100,000 mU/L (around 5000 ng/mL). Magnetic Resonance Imaging (MRI) plays a crucial role in assessing the size of these tumors and evaluating their impact on surrounding structures, such as the optic chiasm, which is important for visual function.

The primary goal of treating hyperprolactinemia, the condition caused by high prolactin levels, is to alleviate symptoms such as inappropriate lactation, restore fertility, and prevent bone demineralization due to insufficient estrogen in women or testosterone in men. Treatment is tailored to the underlying cause. If hyperprolactinemia stems from certain medications, especially antipsychotics, adjustments often require careful discussion with mental health professionals.

In the case of prolactinomas, they are highly responsive to dopamine agonists, making these medications the first-line treatment. Bromocriptine has been used historically but can cause nausea due to its interaction with various dopamine receptor subtypes. A more effective alternative, cabergoline, is taken orally and typically administered twice weekly. Long-term treatment often results in normalized prolactin levels, particularly for smaller microprolactinomas, which may be cured after five years of therapy.

While large macroprolactinomas may necessitate ongoing treatment, recent concerns surrounding the use of ergot-derived drugs like cabergoline have emerged. Research indicates a potential link to sclerotic heart valve pathology; however, these findings are primarily associated with higher doses used for conditions such as Parkinson's disease, rather than the doses utilized for hyperprolactinemia.

Management of prolactinomas during pregnancy presents unique challenges. Although there is no strong evidence suggesting a teratogenic effect from dopamine agonists, these medications are generally discontinued when pregnancy is confirmed. This aspect of treatment necessitates careful monitoring to ensure both maternal health and fetal development are safeguarded throughout the pregnancy.